Modern approaches to HLA-haploidentical blood or marrow transplantation

Nature Reviews Clinical Oncology

Volumn 13, Issue 1, 2016, Pages 10-24

  Kanakry, Christopher G ^a   Fuchs, Ephraim J ^a   Luznik, Leo ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; CD34 ANTIGEN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; APLASTIC ANEMIA; B LYMPHOCYTE; CANCER MORTALITY; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROBABILITY; REVIEW; SURVIVAL RATE; T CELL DEPLETION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ALLOTRANSPLANTATION; BLOOD; BONE MARROW TRANSPLANTATION; EVIDENCE BASED MEDICINE; GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE DEPLETION; PROCEDURES; TREATMENT OUTCOME;

ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; EVIDENCE-BASED MEDICINE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HAPLOIDY; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84951904997     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.128     Document Type: Review

References (169)

1. Thomas, E. et al. Bone-marrow transplantation (first of two parts). N. Engl. J. Med. 292, 832-843 (1975).
2. Ottinger, H., Grosse-Wilde, M., Schmitz, A. & Grosse-Wilde, H. Immunogenetic marrow donor search for 1012 patients: A retrospective analysis of strategies, outcome and costs. Bone Marrow Transplant. 14, S34-S38 (1994).
3. Gragert, L. et al. HLA match likelihoods for haematopoietic stem-cell grafts in the U. S. registry. N. Engl. J. Med. 371, 339-348 (2014).
4. Powles, R. L. et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1, 612-615 (1983).
5. Beatty, P. G. et al. Marrow transplantation from related donors other than HLA-identical siblings. N. Engl. J. Med. 313, 765-771 (1985).
6. Anasetti, C. et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N. Engl. J. Med. 320, 197-204 (1989).
7. Anasetti, C. et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum. Immunol. 29, 79-91 (1990).
8. Szydlo, R. et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J. Clin. Oncol. 15, 1767-1777 (1997).
9. Guinan, E. C. et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704-1714 (1999).
10. Sykes, M. et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353, 1755-1759 (1999).
11. Ogawa, H. et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp. Hematol. 36, 1-8 (2008).
12. von Reyn Cream, L., Ehmann, W. C., Rybka, W. B. & Claxton, D. F. Sirolimus in unmanipulated haploidentical cell transplantation. Bone Marrow Transplant. 42, 765-766 (2008).
13. Peccatori, J. et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 29, 396-405 (2015).
14. Rizzieri, D. A. et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J. Clin. Oncol. 25, 690-697 (2007).
15. Andre-Schmutz, I. et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: A phase 1/2 study. Lancet 360, 130-137 (2002).
16. Bastien, J. P., Roy, J. & Roy, D. C. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin. Oncol. 39, 674-682 (2012).
17. Kasamon, Y. L. et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol. Blood Marrow Transplant. 16, 482-489 (2010).
18. Wang, Y. et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 124, 843-850 (2014).
19. Lu, D. P. et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107, 3065-3073 (2006).
20. Chen, X. H. et al. HLA-haploidentical blood and bone marrow transplantation with anti-Thymocyte globulin: long-Term comparison with HLA-identical sibling transplantation. Blood Cells Mol. Dis. 43, 98-104 (2009).
21. Bashey, A. et al. T-cell-replete HLA-haploidentical haematopoietic transplantation for haematologic malignancies using post-Transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J. Clin. Oncol. 31, 1310-1316 (2013).
22. Raiola, A. M. et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol. Blood Marrow Transplant 20, 1573-1579 (2014).
23. Di Stasi, A. et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leucocyte antigen-matched unrelated and related donors. Biol. Blood Marrow Transplant. 20, 1975-1981 (2014).
24. Dupont, B., O'Reilly, R. J., Pollack, M. S. & Good, R. A. Histocompatibility testing for clinical bone marrow transplantation and prospects for identification of donors other than HLA genotypically identical siblings. Haematol. Blood Transfus. 25, 121-134 (1980).
25. Hansen, J. A., Clift, R. A., Mickelson, E. M., Nisperos, B. & Thomas, E. D. Marrow transplantation from donors other than HLA identical siblings. Hum. Immunol. 2, 31-40 (1981).
26. Przepiorka, D. et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15, 825-828 (1995).
27. Korngold, R. & Sprent, J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 148, 1687-1698 (1978).
28. Kernan, N. A. et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68, 770-773 (1986).
29. Reisner, Y., Ravid, A. & Sharon, N. Use of soybean agglutinin for the separation of mouse B and T lymphocytes. Biochem. Biophys Res. Commun. 72, 1585-1591 (1976).
30. Reisner, Y., Itzicovitch, L., Meshorer, A. & Sharon, N. Haemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc. Natl Acad. Sci. USA 75, 2933-2936 (1978).
31. Reisner, Y., Kapoor, N., O'Reilly, R. J. & Good, R. A. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 2, 1320-1324 (1980).
32. Reisner, Y. et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 2, 327-331 (1981).
33. Reisner, Y. et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61, 341-348 (1983).
34. Jabado, N. et al. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Paediatrics 98, 420-428 (1996).
35. Ash, R. C. et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 7, 443-452 (1991).
36. Suchin, E. J. et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166, 973-981 (2001).
37. Reisner, Y. et al. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc. Natl Acad. Sci. USA 83, 4012-4015 (1986).
38. Kernan, N. A., Flomenberg, N., Dupont, B. & O'Reilly, R. J. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 43, 842-847 (1987).
39. Schwartz, E., Lapidot, T., Gozes, D., Singer, T. S. & Reisner, Y. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors. J. Immunol. 138, 460-465 (1987).
40. Lapidot, T. et al. Booster irradiation to the spleen following total body irradiation. A new immunosuppressive approach for allogeneic bone marrow transplantation. J. Immunol. 141, 2619-2624 (1988).
41. Lapidot, T., Terenzi, A., Singer, T. S., Salomon, O. & Reisner, Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 73, 2025-2032 (1989).
42. Terenzi, A. et al. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 50, 717-720 (1990).
43. Cobbold, S. P., Martin, G., Qin, S. & Waldmann, H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 323, 164-166 (1986).
44. Lapidot, T. et al. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc. Natl Acad. Sci. USA 87, 4595-4599 (1990).
45. Bachar-Lustig, E., Rachamim, N., Li, H. W., Lan, F. & Reisner, Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat. Med. 1, 1268-1273 (1995).
46. Rachamim, N. et al. Tolerance induction by "megadose" haematopoietic transplants: donor-Type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65, 1386-1393 (1998).
47. Reisner, Y., Gur, H., Reich-Zeliger, S., Martelli, M. F. & Bachar-Lustig, E. Haematopoietic stem cell transplantation across major genetic barriers: Tolerance induction by megadose CD34 cells and other veto cells. Ann. N. Y. Acad. Sci. 996, 72-79 (2003).
48. Aversa, F. et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84, 3948-3955 (1994).
49. Aversa, F. et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339, 1186-1193 (1998).
50. Aversa, F. et al. Full haplotype-mismatched haematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23, 3447-3454 (2005).
51. Ciceri, F. et al. A survey of fully haploidentical haematopoietic stem cell transplantation in adults with high-risk acute leukemia: A risk factor analysis of outcomes for patients in remission at transplantation. Blood 112, 3574-3581 (2008).
52. Lang, P. et al. Long-Term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol. Dis. 33, 281-287 (2004).
53. Klingebiel, T. et al. Results and factors influencing outcome after fully haploidentical haematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of centre size: An analysis on behalf of the Acute Leukemia and Paediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 115, 3437-3446 (2010).
54. Walker, I. et al. Canadian multicentre pilot trial of haploidentical donor transplantation. Blood Cells Mol. Dis. 33, 222-226 (2004).
55. Waller, E. K. et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol. Dis. 33, 233-237 (2004).
56. Mehta, J. et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-centre experience of 201 patients. Bone Marrow Transplant. 33, 389-396 (2004).
57. Handgretinger, R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin. Oncol. 39, 664-73 (2012).
58. Bethge, W. A. et al. Haploidentical allogeneic haematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update. Blood Cells Mol. Dis. 40, 13-19 (2008).
59. Lang, P. et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br. J. Haematol. 165, 688-698 (2014).
60. Amrolia, P. J. et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108, 1797-1808 (2006).
61. Bacchetta, R. et al. Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-Anergized donor T cells. Front. Immunol. 5, 16 (2014).
62. Devaud, C. et al. Antitumour activity of γδ T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumour model. Cancer Res. 69, 3971-3978 (2009).
63. Scheper, W. et al. γδ T cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 27, 1328-1338 (2013).
64. Fujishima, N. et al. Skewed T cell receptor repertoire of Vδ1(+) γδ T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. Clin. Exp. Immunol. 149, 70-79 (2007).
65. Lamb, L. S. Jr et al. Human γδ(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 27, 601-606 (2001).
66. Drobyski, W. R., Majewski, D. & Hanson, G. Graft-facilitating doses of ex vivo activated γδ T cells do not cause lethal murine graft-vs.-host disease. Biol. Blood Marrow Transplant. 5, 222-230 (1999).
67. Drobyski, W. R., Vodanovic-Jankovic, S. & Klein, J. Adoptively transferred γδ T cells indirectly regulate murine graft-versus-host reactivity following donor leucocyte infusion therapy in mice. J. Immunol. 165, 1634-1640 (2000).
68. Schumm, M. et al. Depletion of T-cell receptor αβ and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 15, 1253-1258 (2013).
69. Bertaina, A. et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood 124, 822-826 (2014).
70. Di Ianni, M. et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928 (2011).
71. Martelli, M. F. et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124, 638-644 (2014).
72. Leen, A. M. et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114, 4283-4292 (2009).
73. Melenhorst, J. J. et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol. Ther. 23, 179-183 (2015).
74. Ciceri, F. et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A non-randomised phase I-II study. Lancet Oncol. 10, 489-500 (2009).
75. Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
76. Storek, J., Mohty, M. & Boelens, J. J. Rabbit anti-T cell globulin in allogeneic haematopoietic cell transplantation. Biol. Blood Marrow Transplant. 21, 959-970 (2015).
77. Pan, L., Delmonte, J. Jr, Jalonen, C. K. & Ferrara, J. L. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86, 4422-4429 (1995).
78. Coghill, J. M. et al. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 117, 3268-3276 (2011).
79. Zeng, D., Dejbakhsh-Jones, S. & Strober, S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 90, 453-463 (1997).
80. Arpinati, M., Green, C. L., Heimfeld, S., Heuser, J. E. & Anasetti, C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95, 2484-2490 (2000).
81. Mielcarek, M., Graf, L., Johnson, G. & Torok-Storb, B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 92, 215-222 (1998).
82. Mielcarek, M., Martin, P. J. & Torok-Storb, B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 89, 1629-1634 (1997).
83. Tanaka, J., Mielcarek, M. & Torok-Storb, B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood 91, 347-352 (1998).
84. Huang, X. J., Chang, Y. J. & Zhao, X. Y. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl. Immunol. 17, 193-197 (2007).
85. Volpi, I. et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leucocyte antigen haplotype-mismatched haematopoietic transplants. Blood 97, 2514-2521 (2001).
86. Ji, S. Q. et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: An excellent alternative for high-risk leukemia. Bone Marrow Transplant. 30, 861-866 (2002).
87. Huang, X. J. et al. Haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of haematological malignancies. Bone Marrow Transplant. 38, 291-297 (2006).
88. Liu, D. et al. Haploidentical haematopoietic stem cell transplantation without in vitro T cell depletion for treatment of haematological malignancies in children. Biol. Blood Marrow Transplant. 14, 469-477 (2008).
89. Lee, K. H. et al. Reduced-intensity conditioning therapy with busulphan, fludarabine, and antithymocyte globulin for HLA-haploidentical haematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 118, 2609-2617 (2011).
90. Chen, H. R. et al. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp. Haematol. 31, 1019-1125 (2003).
91. Ji, S. Q. et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for haematological malignancies. Bone Marrow Transplant. 36, 349-354 (2005).
92. Di Bartolomeo, P. et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk haematologic malignancies. Blood 121, 849-857 (2013).
93. Luo, Y. et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124, 2735-2743 (2014).
94. Wang, Y. et al. Haploidentical-versus identical-sibling transplant for AML in remission: A multi-centre, prospective study. Blood 125, 3956-3962 (2013).
95. Wang, Y. et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: An historic comparison. Biol. Blood Marrow Transplant. 17, 821-830 (2011).
96. Huang, X. J. et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol. Blood Marrow Transplant. 15, 257-265 (2009).
97. Chen, H. et al. Haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol. Blood Marrow Transplant. 21, 1110-1116 (2015).
98. Mo, X. D. et al. Haploidentical haematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high-And low-risk groups. Int. J. Cancer 136, 1697-1707 (2015).
99. Sun, Y. Q. et al. Haploidentical haematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL. Bone Marrow Transplant. 50, 20-25 (2015).
100. Huo, M. R. et al. The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. Clin. Transplant. 26, 284-291 (2012).
101. Maguire, H. C. Jr, Maibach, H. I. & Minisce, L. W. Jr. Inhibition of guinea pig anaphylactic sensitization with cyclophosphoramide. J. Invest. Dermatol. 36, 235-236 (1961).
102. Berenbaum, M. C. & Brown, I. N. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 200, 84 (1963).
103. Mayumi, H. & Tokunaga, K. Cyclophosphamide-induced chimera-Type tolerance to allografts: An overview of drug-induced immunological tolerance. Fukuoka Igaku Zasshi 81, 20-39 (1990).
104. Mayumi, H., Umesue, M. & Nomoto, K. Cyclophosphamide-induced immunological tolerance: An overview. Immunobiology 195, 129-139 (1996).
105. Eto, M. et al. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J. Immunol. 145, 1303-1310 (1990).
106. Kong, Y. Y. et al. Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo. J. Immunol. 157, 5284-5289 (1996).
107. Nomoto, K., Eto, M., Yanaga, K., Nishimura, Y. & Maeda, T. Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J. Immunol. 149, 2668-2674 (1992).
108. Dukor, P. & Dietrich, F. M. Prevention of cyclophosphamide-induced tolerance to erythrocytes by pretreatment with cortisone. Proc. Soc. Exp. Biol. Med. 133, 280-285 (1970).
109. Nishimura, Y. et al. Recombinant human granulocyte colony-stimulating factor improves the compromised state of recipient mice without affecting the induction of specific tolerance in the cyclophosphamide-induced tolerance system. J. Immunol. 146, 2639-2647 (1991).
110. Mayumi, H. & Good, R. A. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J. Exp. Med. 169, 213-238 (1989).
111. Colson, Y. L. et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and haematopoietic histocompatibility barriers. J. Immunol. 155, 4179-4188 (1995).
112. Luznik, L., Engstrom, L. W., Iannone, R. & Fuchs, E. J. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol. Blood Marrow Transplant. 8, 131-138 (2002).
113. Luznik, L., Jalla, S., Engstrom, L. W., Iannone, R. & Fuchs, E. J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98, 3456-3464 (2001).
114. Colson, Y. L. et al. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J. Immunol. 157, 2820-2829 (1996).
115. Ross, D., Jones, M., Komanduri, K. & Levy, R. B. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-Transplantation administration of cyclophosphamide after haematopoietic cell transplantation. Biol. Blood Marrow Transplant. 19, 1430-1438 (2013).
116. Ganguly, S. et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood 124, 2131-2141 (2014).
117. Kanakry, C. G. et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci. Transl. Med. 5, 211ra157 (2013).
118. Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638-647 (2009).
119. Chen, B. J., Cui, X., Liu, C. & Chao, N. J. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99, 3083-3088 (2002).
120. Guimond, M. et al. P-glycoprotein targeting: A unique strategy to selectively eliminate immunoreactive T cells. Blood 100, 375-382 (2002).
121. Bastien, J. P. et al. Photodepletion differentially affects CD4+ TREGS versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood 116, 4859-4869 (2010).
122. Nirmul, G., Severin, C. & Taub, R. N. Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice. Transplant. Proc. 5, 675-678 (1973).
123. O'Donnell, P. V. et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 8, 377-386 (2002).
124. Luznik, L. et al. HLA-haploidentical bone marrow transplantation for haematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641-650 (2008).
125. Luznik, L., O'Donnell, P. V. & Fuchs, E. J. Post-Transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin. Oncol. 39, 683-693 (2012).
126. Munchel, A. et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-Transplantation cyclophosphamide. Paediatr. Rep. 3, e15 (2011)
127. McCurdy, S. R. et al. Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 125, 3024-3031 (2015).
128. Raiola, A. M. et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for haematologic malignancies after myeloablative conditioning. Biol. Blood Marrow Transplant. 19, 117-122 (2013).
129. Solomon, S. R. et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk haematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol. Blood Marrow Transplant. 18, 1859-1866 (2012).
130. Solomon, S. R. et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol. Blood Marrow Transplant. 21, 1299-1307 (2015)
131. Grosso, D. et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing. Blood 118, 4732-4739 (2011).
132. Grosso, D. et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol. Blood Marrow Transplant. 21, 646-652 (2014).
133. Raj, K. et al. Peripheral blood haematopoietic stem cells for transplantation of haematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol. Blood Marrow Transplant. 20, 890-895 (2014).
134. Castagna, L. et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-Transplantation cyclophosphamide. Biol. Blood Marrow Transplant. 20, 724-729 (2014).
135. Anasetti, C. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl. J. Med. 367, 1487-1496 (2012).
136. O'Donnell, P., Raj, K. & Pagliuca, A. High fever occurring 4 to 5 days post-Transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-Transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol. Blood. Marrow Transplant. 21, 197-198 (2015).
137. Crocchiolo, R. et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl. Infect. Dis. 17, 242-249 (2015).
138. Gladstone, D. E. et al. Partially mismatched transplantation and human leucocyte antigen donor-specific antibodies. Biol. Blood Marrow Transplant. 19, 647-652 (2013).
139. Ciurea, S. O. et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88, 1019-1024 (2009).
140. Leffell, M. S., Jones, R. J. & Gladstone, D. E. Donor HLA-specific Abs: To BMT or not to BMT? Bone Marrow Transplant. 50, 751-758 (2015).
141. Kanakry, J. A. et al. Absence of post-Transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-Transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol. Blood Marrow Transplant. 19, 1514-1517 (2013).
142. Symons, H. J. et al. Rarity of donor-derived malignancy after allogeneic BMT with high-dose post-Transplantation cyclophosphamide. Biol. Blood Marrow Transplant. 20, S252 (2014).
143. Kanakry, C. G. & Luznik, L. Are alternative donors really still "alternative?" Biol. Blood Marrow Transplant. 20, 1463-1464 (2014).
144. Ciurea, S. O. et al. Haploidentical transplant with post-Transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood http://dx.doi.org/10.1182/blood-2015-04-639831.
145. Kanakry, J. A. et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol. Blood Marrow Transplant. 19, 602-606 (2013).
146. Garciaz, S. et al. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant. 50, 865-867 (2015).
147. Burroughs, L. M. et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related haematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol. Blood Marrow Transplant. 14, 1279-1287 (2008).
148. Raiola, A. et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-Transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 49, 190-194 (2014).
149. Castagna, L. et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 49, 1475-1480 (2014).
150. Ciurea, S. O. et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical haematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 18, 1835-1844 (2012).
151. Brunstein, C. G. et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118, 282-288 (2011).
152. Eapen, M. et al. Mismatched related and unrelated donors for allogeneic haematopoietic cell transplantation for adults with haematologic malignancies. Biol. Blood Marrow Transplant. 20, 1485-1492 (2014).
153. El-Cheikh, J. et al. Unrelated cord blood compared with haploidentical grafts in patients with haematological malignancies. Cancer 121, 1809-1816 (2015).
154. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01597778 (2015).
155. Luznik, L. et al. High-dose cyclophosphamide as single-Agent, short-course prophylaxis of graft-versus-host disease. Blood 115, 3224-3330 (2010).
156. Kanakry, C. G. et al. Single-Agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124, 3817-3827 (2014).
157. Kanakry, C. G. et al. Multi-institutional study of post-Transplantation cyclophosphamide as single-Agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulphan and fludarabine conditioning. J. Clin. Oncol. 32, 3497-3505 (2014).
158. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02345850 (2015).
159. Holtick, U. et al. OCTET-CY: A phase II study to investigate the efficacy of post-Transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur. J. Haematol. https://dx.http://dx.doi.org/10.1111/ejh.12541.
160. Bradstock, K. F. et al. Single-Agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leucocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol. Blood Marrow Transplant. 21, 941-944 (2015).
161. Alousi, A. M. et al. Phase II trial of graft-versus-host disease prophylaxis with post-Transplantation cyclophosphamide after reduced-intensity busulphan/fludarabine conditioning for haematological malignancies. Biol. Blood Marrow Transplant. 21, 906-912 (2015).
162. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02208037 (2015).
163. Solomon, S. R. et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-Transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 20, 1828-1834 (2014).
164. Leventhal, J. et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and haematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra28 (2012).
165. Leventhal, J. et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 95, 169-176 (2013).
166. Leventhal, J. R. et al. Immune reconstitution/immunocompetence in recipients of kidney plus haematopoietic stem/facilitating cell transplants. Transplantation 99, 288-298 (2015).
167. Vago, L. et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361, 478-488 (2009).
168. Jagasia, M. H. et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol. Blood Marrow Transplant. 21, 389-401.e1 (2015).
169. Bhatia, S. et al. Late mortality after allogeneic haematopoietic cell transplantation and functional status of long-Term survivors: report from the bone marrow transplant survivor study. Blood 110, 3784-3792 (2007).